| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.072 | 0.03 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.1 | 0.03 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.099 | 0.03 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.08 | 0.03 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.07 | 0.03 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.03 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.082 | 0.03 |